5 recruiting, 4 not yet recruiting. 4 Phase 2, 2 Phase 4, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Tafolecimab: new trials by email Literature Review of Tafolecimab trials Research Report on Tafolecimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer Tafolecimab, Sintilimab - Colon Cancer, PCSK9 Inhibitor | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 70 | 2026-09-20 | 2026-09-25 |
| INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2) Tafolecimab, Placebo - Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | Not applicable | Not yet recruiting | Beijing Tiantan Hospital | 242 | 2026-09-08 | 2026-10-08 |
| Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals Tafolecimab - Hyperlipidemia | Not yet recruiting | Mei Gao | 60 | 2026-08-01 | 2026-07-17 | |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients Tafolecimab - Acute Myocardial Infarction (AMI) | Phase 4 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 1160 | 2025-11-20 | 2025-11-21 |
| Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Tafolecimab, Sintilimab (approved), Etoposide - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2025-07-30 | 2026-09-15 |
| A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. Tafolecimab, Sintilimab, Nab paclitaxel - Lung Cancer | Phase 2 | Recruiting | Jinghui Wang | 30 | 2024-05-17 | 2024-05-20 |
| Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population Tafolecimab, Cholesterol Absorption Inhibitor, Statin - Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 3684 | 2023-11-11 | 2026-10-27 |
Acute Coronary Syndrome (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Hyperlipidemias (1) · Ischemic Stroke (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1) · Urinary Bladder Neoplasms (1)
Beijing Tiantan Hospital (1) · China National Center for Cardiovascular Diseases (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Guangdong Provincial People's Hospital (1) · Jinghui Wang (1) · Mei Gao (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The Affiliated Hospital of Xuzhou Medical University (1)
China (9)
Na-Qiong Wu, Doctor (1) · Yong Huo, M.D. and Ph.D. (1) · Yong-Jian Wu, Doctor (1) · Yuan Lu, M.D. and Ph.D. (1)